183504-77-0

Upstream product

• 3393-45-1 5,6-dihydro-pyran-2-one 
• 1679-18-1 4-Chlorophenylboronic acid 
• 183504-76-9 (R)-3-(4-chlorophenyl)-glutaric acid monoethyl ester 
• 101104-10-3 diethyl 3-(4-chlorophenyl)glutarate 

Downstream Products

• 1207950-29-5 C₁₁H₁₄ClNO₃ 
• 183504-79-2 (R)-7-(tert-Butyl-diphenyl-silanyloxy)-5-(4-chloro-phenyl)-heptanoic acid methyl ester 
• 1027075-57-5 (R)-7-(tert-Butyl-diphenyl-silanyloxy)-5-(4-chloro-phenyl)-heptanoyl chloride 
• 183504-74-7 (E)-(R)-7-(tert-Butyl-diphenyl-silanyloxy)-5-(4-chloro-phenyl)-hept-2-enoic acid ethyl ester 
• 183504-75-8 3-[5-bromo-3-(4-chlorophenyl)pentyl]-4-(4-methoxyphenyl)-1-phenyl-2-azetidinone 
• 183504-82-7 (3R,4S)-3-[3-(4-chlorophenyl)-5-hydroxypentyl]-4-(4-methoxyphenyl)-1-phenyl-2-azetidinone 
• 183504-78-1 (E)-(R)-5-(4-Chloro-phenyl)-7-hydroxy-hept-2-enoic acid ethyl ester 

Relevant academic research and scientific papers

Rhodium-catalyzed asymmetric 1,4-addition of arylboron reagents to α,β-unsaturated esters

Reaction of arylboron reagents, arylboronic acids or arylborates, which are readily accessible by lithiation of aryl bromides followed by treatment with trimethoxyborane, with α,β-unsaturated esters in the presence of rhodium/(S)-binap catalyst proceeded with high enantioselectivity to give high yields of optically active β-aryl esters of up to 98% ee. The enantioselectivity depends on the steric bulkiness of the ester moiety.

Design of N-sulfinyl homoallylic amines as novel sulfinamide-olefin hybrid ligands for asymmetric catalysis: Application in Rh-catalyzed enantioselective 1,4-additions

Here we show that simple and readily available chiral sulfinamide-olefins can display great catalytic activities and enantioselectivities in rhodium-catalyzed 1,4-addition reactions. This study represent the first example of chiral sulfur-based olefin ligand class for transition metal-catalyzed asymmetric transformation.

Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease

(Chemical Equetion Presentation) Botulinum neurotoxin serotype A (BoNT/A) is the most toxic protein known to man and also a bioterrorism agent. As defined by our previous research targeting the etiological agent responsible for BoNT/A intoxication, a protease, we now report on the asymmetric synthesis of four new BoNT/A inhibitors; the most potent of this series is roughly 2-fold more active than the best small molecule inhibitor currently known.